S. J. Russell, K. W. Peng, and J. C. Bell, Oncolytic virotherapy, Nat Biotechnol, vol.30, pp.658-670, 2012.

B. D. Lichty, C. J. Breitbach, D. F. Stojdl, and J. C. Bell, Going viral with cancer immunotherapy, Nat Rev Cancer, vol.14, pp.559-567, 2014.

O. Kepp, L. Senovilla, I. Vitale, E. Vacchelli, and S. Adjemian, Consensus guidelines for the detection of immunogenic cell death, Oncoimmunology, vol.3, p.955691, 2014.

S. W. Brubaker, K. S. Bonham, I. Zanoni, and J. C. Kagan, Innate immune pattern recognition: a cell biological perspective, Annu Rev Immunol, vol.33, pp.257-290, 2015.

J. F. Fonteneau, J. B. Guillerme, F. Tangy, and M. Grégoire, Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells, Oncoimmunology, vol.2, p.24212, 2013.

A. Gauvrit, S. Brandler, C. Sapede-peroz, N. Boisgerault, and F. Tangy, Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response, Cancer Res, vol.68, pp.4882-4892, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-00330770

J. B. Guillerme, N. Boisgerault, D. Roulois, J. Menager, and C. Combredet, Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells, Clin Cancer Res, vol.19, pp.1147-1158, 2013.

R. H. Andtbacka, H. L. Kaufman, F. Collichio, T. Amatruda, and N. Senzer, Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, vol.33, pp.2780-2788, 2015.

J. M. Burke, D. L. Lamm, M. V. Meng, J. J. Nemunaitis, and J. J. Stephenson, A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer, J Urol, vol.188, pp.2391-2397, 2012.

M. C. Coffey, J. E. Strong, P. A. Forsyth, and P. W. Lee, Reovirus therapy of tumors with activated Ras pathway, Science, vol.282, pp.1332-1334, 1998.

R. Chakrabarty, H. Tran, G. Selvaggi, A. Hagerman, and B. Thompson, The oncolytic virus, pelareorep, as a novel anticancer agent: a review, Invest New Drugs, vol.33, pp.761-774, 2015.

J. Heo, T. Reid, L. Ruo, C. J. Breitbach, and S. Rose, Randomized dosefinding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat Med, vol.19, pp.329-336, 2013.

, Global Partners SillaJen, Transgene and Lee's Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec, Transgene, 2014.

E. Galanis, P. J. Atherton, M. J. Maurer, K. L. Knutson, and S. C. Dowdy, Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer, Cancer Res, vol.75, pp.22-30, 2015.

J. B. Guillerme, M. Gregoire, F. Tangy, and J. F. Fonteneau, Antitumor Virotherapy by Attenuated Measles Virus (MV), Biology (Basel), vol.2, pp.587-602, 2013.

S. Berchtold, J. Lampe, T. Weiland, I. Smirnow, and S. Schleicher, Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis, J Virol, vol.87, pp.3484-3501, 2013.

J. L. Perez-gracia, S. Labiano, M. E. Rodriguez-ruiz, M. F. Sanmamed, and I. Melero, Orchestrating immune check-point blockade for cancer immunotherapy in combinations, Curr Opin Immunol, vol.27, pp.89-97, 2014.

, Recent Progresses of Oncolytic Immunotherapy, Citation: Fonteneau JF, vol.1, p.101, 2015.